Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 2/20 | 0.47 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | F11 | P03951 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29717083 | 1.00 | C3AR1 (0.47) | C3AR1SUCNR1UTS2RROCK2ROCK1 | |
| SCHEMBL24301578 | 1.00 | C3AR1 (0.47) | C3AR1SUCNR1UTS2RROCK2ROCK1 | |
| SCHEMBL24302628 | 0.92 | SUCNR1 (0.42) | C3AR1SUCNR1UTS2RROCK2ROCK1 | |
| SCHEMBL26667467 | 0.92 | SUCNR1 (0.42) | C3AR1SUCNR1UTS2RROCK2ROCK1 | |
| SCHEMBL26667414 | 0.89 | HDAC1 (0.44) | C3AR1SUCNR1UTS2RROCK2ROCK1 | |
| SCHEMBL26667420 | 0.89 | HDAC1 (0.44) | C3AR1SUCNR1UTS2RROCK2ROCK1 | |
| SCHEMBL24301574 | 0.87 | F11 (0.43) | F11KLKB1 | |
| SCHEMBL26667498 | 0.87 | F11 (0.43) | F11KLKB1 | |
| SCHEMBL29717134 | 0.86 | HDAC1 (0.42) | C3AR1SUCNR1UTS2RROCK2ROCK1 | |
| SCHEMBL30504327 | 0.86 | HDAC1 (0.44) | C3AR1SUCNR1UTS2RROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| WO-2022078294-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | SSB, BTK, PADI6 | C3AR1 4425/4885SUCNR1 1963/4885UTS2R 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.